13-Valent Pneumococcal Conjugate Vaccine Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pneumococcal conjugate vaccines, such as Prevnar and PCV-13, have limited coverage against certain serotypes of Streptococcus pneumoniae, particularly in infants and young children, leading to increased invasive pneumococcal diseases, and there is a need for a vaccine with improved immunogenic properties to address serotype replacement and regional variations.
Innovation Solution
A 13-valent pneumococcal conjugate vaccine composition that includes capsular polysaccharides from 13 serotypes, including serotype 2 or 9N, conjugated to the carrier protein CRM 197, with an adjuvant like aluminum phosphate, to enhance immune response and provide broader protection against pneumococcal disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polysaccharide vaccines are used to prevent pneumococcal disease, then protection against covered serotypes is achieved, but infants and young children respond poorly due to T-cell independent immune response
Solution Approach 1:
The patent combines polysaccharide antigens with protein carriers (CRM197) to create conjugate vaccines. This composite structure transforms the T-cell independent polysaccharide response into a T-cell dependent response, significantly improving immunogenicity in infants and young children while maintaining protection against the target serotypes.
2Reliability
If 7-valent pneumococcal conjugate vaccine is used, then immunogenicity and effectiveness against covered serotypes is improved, but coverage of serotypes is limited and invasive pneumococcal diseases caused by uncovered serotypes have increased
Solution Approach 1:
The patent creates a 13-valent vaccine that maintains the successful conjugate platform of the 7-valent vaccine while expanding serotype coverage to include 6 additional serotypes (1, 3, 5, 6A, 7F, 19A). This multi-functional approach preserves the immunogenic advantages of conjugate vaccines while broadening protective coverage against diverse pneumococcal serotypes.
Solution Approach 2:
The vaccine is divided into 13 distinct polysaccharide-protein conjugates, each targeting a specific serotype. This segmentation allows the vaccine to cover multiple serotypes simultaneously while maintaining the immunogenic properties of individual conjugate components, addressing serotype replacement issues through comprehensive coverage.
3Adaptability or versatility
If 13-valent pneumococcal conjugate vaccine with additional serotypes is developed, then serotype coverage is expanded, but vaccine composition complexity increases
Solution Approach 1:
The patent merges 13 different polysaccharide-protein conjugates into a single vaccine formulation. This combining approach expands serotype coverage while managing complexity through a unified conjugate platform, allowing all 13 serotypes to be delivered in one injection rather than requiring multiple separate vaccines.
Data Source
AI summary
Provided is an immunogenic composition comprising 13 different polysaccharide-protein conjugates. Each of the conjugates comprises a capsular polysaccharide prepared from a different serotype Streptococcus pneumoniae conjugated to a carrier protein, that is, 12 serotypes selected from the group consisting of 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F and serotype 2 or 9N. The immunogenic composition formulated into a vaccine comprising an aluminum-based adjuvant increases coverage with respect to pneumococcal diseases in infants and children.